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Abstract 
 
Cloning and characterization of the orphan nuclear receptors constitutive 
androstane receptor (CAR, NR1I3) and pregnane X receptor (PXR, NR1I2) led to 
major breakthroughs in studying drug-mediated transcriptional induction of drug-
metabolizing cytochromes P450 (CYP). More recently, additional roles for CAR 
and PXR have been discovered. As examples, these xenosensors are involved 
in the homeostasis of cholesterol, bile acids, bilirubin and other endogenous 
hydrophobic molecules in the liver: CAR and PXR thus form an intricate 
regulatory network with other members of the nuclear receptor superfamily, 
foremost the cholesterol-sensing liver X receptor (LXR, NR1H2/3) and the bile-
acid-activated farnesoid X receptor (FXR, NR1H4). In this review, functional 
interactions between these nuclear receptors as well as the consequences on 
physiology and pathophysiology of the liver are discussed. 
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Metabolism of drugs and other xenobiotics in the liver is our body’s primary 
defense against accumulation of potentially toxic, lipophilic compounds. The 
superfamily of cytochromes P450 (CYPs) are the best-studied class of enzymes 
in this task [1]. Transcriptional and post-transcriptional regulation of CYPs after 
exposure to certain drugs or other xenobiotics has been described several 
decades ago. Classically, the barbiturate phenobarbital induces its own 
metabolism and excretion by elevating CYP levels [2]. However, the molecular 
mechanisms underlying this observation remained a conundrum until the 
discovery and subsequent characterization of the constitutive androstane 
receptor (CAR, official nomenclature NR1I3) and the pregnane X receptor (PXR, 
NR1I2, alternatively called PAR or SXR), two members of the superfamily of 
nuclear receptors [3-7]. Mice with genetic ablations of CAR and PXR have 
significantly reduced inducibility of CYPs by a variety of drugs [8, 9]. Whereas 
these two receptors share some common ligands and also have an overlapping 
target gene pattern [10-13], the mode of activation for CAR and PXR is quite 
different [14]. PXR is located in the nucleus, it has a low basal activity and is 
highly activated upon ligand binding [14, 15]. In contrast, in the non-induced 
state, CAR resides in the cytoplasm. After treatment with activators such as 
phenobarbital, CAR shuttles to the nucleus to activate its target genes. Moreover, 
CAR localization and activity is regulated by various protein phosphorylation 
events [16-18]. For a more detailed discussion of CAR and PXR functions in 
drug-mediated induction of CYPs, see some recent reviews (e.g. refs. [19-23] 
and references therein). 
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The nuclear receptor NR1I group includes xenosensors and lipid-sensing 
members 
 
Compounds that induce transcription of CYPs and that activate CAR and PXR 
are structurally very diverse [21]. However, most of them are small in size and 
are highly lipophilic [24]. Whereas the CAR ligand-binding domain structure has 
not been solved yet, PXR crystal structures provided evidence for the high 
promiscuity of its ligand binding pocket [25, 26]. The binding cavity is 1150 Ǻ3 in 
size, substantially larger than those of many other members of the nuclear 
receptor superfamily, and has only a small number of polar groups in the smooth, 
hydrophobic ligand binding pocket [25, 26]. CAR and PXR are members of the 
nuclear receptor groups NR1I2 and NR1I3, respectively [27] (Fig. 1). These 
groups also contain the frog benzoate X receptors  and  (BXR/, NR1I2) 
which are functionally and pharmacologically distinct from the xenosensors [28, 
29]. The vitamin D receptor (VDR, NR1I1) is the closest relative of the xenobiotic-
activated nuclear receptors in terms of amino acid sequence similarity and 
belongs to the same subfamily. Fig. 1 depicts the phylogeny of these receptors 
from different species. The liver X receptors  and  (LXR/, NR1H3/2) and the 
farnesoid X receptor (FXR, NR1H4) have several features in common with CAR, 
PXR, and VDR, other members of the NR1I subfamily: they are lipid-activated 
nuclear receptors, they bind their ligands with relative low affinity, often in the 
micromolar range and they heterodimerize with the retinoid X receptor (RXR, 
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NR2B1/2/3) [30]. These receptors belong to the so-called type 2 nuclear receptor 
group, which is characterized by low ligand affinity, binding of endogenous and 
dietary lipids and heterodimerization with RXR [30-32]. In contrast, the “classical” 
steroid hormone receptors belong to the type 1 nuclear receptors that normally 
have high affinity ligands, which are synthesized from endogenous endocrine 
sources. Moreover, the steroid hormone receptors usually bind DNA as a 
homodimer [30-32]. In their initial characterization, ligands of the NR1I receptors 
were drugs and other xenobiotics for CAR and PXR, 1,25-dihydroxyvitamin D3 
for VDR [33], oxysterols for LXR [34] and bile acids for FXR [35-37]. However, 
later findings showed that a number of endogenous compounds are also able to 
influence PXR and CAR activity and that these xenosensors share an 
overlapping ligand pattern with other members of the NR1I and NR1H 
subfamilies (Fig. 2). 
 
Xenosensors in steroid biosynthesis and metabolism 
 
Since some of the CYPs that are regulated by PXR and CAR are involved in 
steroid metabolism, it is not surprising that the activities of both xenosenors are 
also modulated by steroids [38]: PXR is activated by pregnanes, progesterone 
and glucocorticoids [4, 5] whereas androstane metabolites, estrogens and 
progesterone affect CAR activity both positively and negatively [10, 39-41]. 
Transgenic expression of a human constitutively active VP16-PXR fusion protein 
in mouse liver massively increases steroid clearance [42]. In patients, long-term 
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treatment with rifampicin, a strong human PXR activator, phenobarbital or other 
anti-convulsants interferes with the bioavailability and therapeutic efficacy of co-
administrated corticosteroids and steroid-based oral contraceptives [38, 43]. The 
effect of drugs and xenobiotics on endogenous steroid levels is less clear 
because of highly efficient compensatory mechanisms that control 
steroidogenesis and metabolism. However, in some cases, long-term treatment 
of a tuberculosis patient with rifampicin resulted in misdiagnosis of Cushing’s 
syndrome [44]. Phenobarbital was shown to lead to developmental abnormalities 
in animal models due to its effect on steroid clearance which results in a 
demasculinized phenotype [45-47]. Similarly, human epidemiological studies 
suggested that prenatal exposure to phenobarbital increases the risk for 
reproductive development abnormalities [48, 49]. 
 
CAR and PXR confer hepatoprotection upon bile acid exposure 
 
Under standard conditions, PXR knockout mice are viable and show no overt 
phenotype [8]. However, upon challenge with a bile acid-rich diet, PXR null 
animals suffer from a higher degree of bile acid-induced hepatotoxicity compared 
to wild-type littermates [50, 51]. Certain bile acids (e.g. lithocholic acid) have 
been shown to directly activate PXR at concentrations between 10-100 M [50, 
51]. Moreover, three bile acid precursors (7-hydroxy-4-cholesten-3-one, 5-
cholestan-3,7,12-triol, and 4-cholesten-3-one) activate mouse PXR in the low 
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micromolar range but are less potent activators of its human ortholog [52]. This 
species difference in ligand specificity extends to other xenobiotic ligands [53]. 
CAR is also able to confer hepatoprotection from bile acids by increasing their 
sulfation and excretion [54-56]. No direct binding of bile acids to CAR has been 
described. However, several bile acids modulate the activity of a fusion protein of 
GAL4-DNA binding domain combined with the CAR ligand binding domain in 
reporter gene assays [28]. Finally, activation of both PXR and CAR increases 
clearance of bilirubin from hepatocytes [42, 57]. Bilirubin does not directly bind to 
either CAR or PXR [57]. Instead, bilirubin activates CAR indirectly by promoting 
cytoplasmic-nuclear translocation, similar to the effects described for 
phenobarbital on CAR [57]. The overlap of endogenous lipids to activate CAR, 
PXR, FXR and LXR suggests a functional connection between these receptors in 
liver physiology. The best studied example is the regulation of cholesterol 
biosynthesis and metabolism to bile acids (Fig. 3). 
 
Nuclear receptor regulation of cholesterol biosynthesis and metabolism 
 
Cholesterol is metabolized by two different pathways. The “classic” bile acid 
biosynthesis pathway is exclusively found in the liver and results in the formation 
of the primary bile acids cholic acid and chenodeoxycholic acid. The “alternative” 
pathway is ubiquitous and produces oxidized cholesterols which have to be 
transported to the liver in order to be converted into bile acids. Under normal 
conditions, the classic pathway is the main bile acid biosynthetic pathway in the 
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liver [58-60]. This pathway is highly regulated, predominantly at its first enzymatic 
step, the cholesterol 7-hydroxylase (CYP7A1). CYP7A1 expression is controlled 
by a variety of factors and stimuli including hormones, oxysterols, bile acids, 
drugs and diurnal rhythm [58, 61]. In the mouse and rat CYP7A1 promoters, LXR 
binds to a nuclear receptor motif arranged as a direct repeat of hexamer halfsites 
with a spacing of 4 nucleotides (DR-4). When activated by oxysterols or other 
ligands, LXR binds to this DR-4 element and strongly induces CYP7A1 
transcription [62, 63]. Interestingly, LXR has much less of an effect on hamster 
and no effect on human CYP7A1 expression [64, 65]. This difference might be 
attributed to a mutation in the DR-4 site in the human CYP7A1 promoter which 
prevents LXR from binding [64]. The ability of LXR to induce Cyp7a1 in mice and 
rats makes these animals extremely resistant to a high cholesterol diet whereas 
other species, including man, rapidly develop hypercholesterolemia under 
comparable conditions. Accordingly, high cholesterol-fed mice that transgenically 
express human CYP7A1 in a mouse Cyp7a1 knockout background lack induction 
of CYP7A1 and become hypercholesterolemic [66, 67]. 
 
The rates of cholesterol biosynthesis and triglyceride biogenesis are 
predominantly controlled by the sterol regulatory-element binding proteins 
(SREBP) [68]. Of the three SREBP isoforms, SREBP-2 coordinately activates the 
genes for cholesterol biosynthesis when hepatic cholesterol is low. On the other 
hand, SREBP-1c induces triglyceride biosynthesis. SREBP-1a, a splice variant of 
the SREBP-1 gene, regulates all SREBP target genes. Cholesterol biosynthesis 
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from acetyl-CoA is a complex process involving 15 enzymatic steps and NADPH 
as co-factor [68]. Major metabolic intermediates in the pathway are acetoacetyl-
CoA, hydroxy-methylglutaryl-CoA, mevalonate and squalene. Several of these 
cholesterol precursors also serve as substrates for other biosynthetic pathways, 
e.g. 7-dehydrocholesterol for the generation of vitamin D3 [30]. In contrast, CAR 
and PXR are activated by precursors in the cholesterol biosynthesis pathway, 
namely isoprenoids and squalene metabolites, respectively [69, 70]. When 
cholesterol biosynthesis is blocked, CAR and PXR might be activated by these 
cholesterol precursors and subsequently inhibit cholesterol metabolism to bile 
acids by repressing CYP7A1 as seen after activation of PXR by other ligands 
[50]. This regulation could prevent cholesterol levels from dropping too low when 
cholesterol biosynthesis is impaired. However, the physiological relevance of 
these activations and the validity of this hypothesis remain to be tested. 
Interestingly, geranylgeranyl-pyrophosphate, another intermediate in mevalonate 
metabolism to cholesterol, inhibits LXR activity and thus also results in lower 
CYP7A1 levels [71]. 
 
A potent product-mediated negative feedback inhibition underlies the regulation 
of bile acid synthesis from cholesterol. By activating FXR, bile acids induce the 
expression of the small heterodimer partner (SHP, NR0B2), a nuclear receptor 
lacking a DNA binding domain. Subsequently, SHP binds to the liver receptor 
homolog-1 (LRH-1, NR5A2) which is a potent activator of CYP7A1. This 
interaction decreases the transcriptional activity of LRH-1 and subsequently 
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lowers CYP7A1 transcription [72, 73]. Surprisingly, bile acids are able to repress 
Cyp7a1 expression in SHP -/- animals suggesting the presence of redundant 
mechanisms [74, 75]. FXR directly activates transcription of the fibroblast growth 
factor 19 which, via a c-jun N-terminal kinase-dependent pathway, leads to 
reduced CYP7A1 expression [76]. Another possible pathway of SHP-
independent CYP7A1 repression might be mediated by PXR. Drugs, other 
xenobiotics and bile acids that activate PXR have been observed to 
downregulate CYP7A1 mRNA expression in hepatocytes and in vivo [50, 77]. 
Apart from its independence from SHP, the exact molecular mechanism of this 
repression has not been elucidated. Preliminary findings imply the hepatic 
nuclear factor 4 (HNF4, NR2A1) to be involved in this process ([58] and C. H. 
and U. A. M., unpublished observations). HNF4 is an important regulator of 
CYP7A1 expression in different species and is at least in part responsible for 
mediating CYP7A1 repression by bile acids [76, 78, 79]. 
 
Similar to FXR, CAR and PXR promote metabolism and excretion of bile acids. 
They partly do so by inducing the same target genes including the canalicular 
bile acid transporter multidrug-resistance-associated protein 2 and 3 
(MRP2/ABCC2 and MRP3/ABCC3) [80-82]. However, the xenosensors also 
increase alternate, compensatory pathways for lowering hepatic bile acid levels 
by inducing their hydroxylation, conjugation and subsequent excretion via blood 
and urine [50, 51, 54, 55, 83]. In contrast, FXR is predominantly responsible for 
triggering bile acid export from the liver into the bile duct followed by excretion of 
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bile acids via feces [84, 85]. PXR induces several bile acid-metabolizing CYPs, 
bile acid transporters and sulfotransferases that serve to detoxify bile acids such 
as lithocholic acid [50, 51, 77, 82, 86]. Activation of CAR by bile acids triggers yet 
another alternate response in the hepatocyte. In addition to CYP2Bs and 
CYP3As, CAR increases sulfation of bile acids [54]. By this mechanism, CAR is 
able to protect the liver from bile acid-induced hepatotoxicity [55]. As a fourth 
layer of defense, VDR is also activated by bile acids [87]. This receptor can then 
increase CYP2B, CYP2C and CYP3A levels [88] and subsequent bile acid 
metabolism [87]. VDR thus activates a similar “emergency” response to high bile 
acid levels as the xenosensors. The more than tenfold difference in affinity for 
bile acid binding to FXR and PXR implies that under physiological conditions, bile 
acids predominantly activate the FXR-mediated pathway and thus their normal 
excretion. However, in disease states where the regular ways for bile acid 
excretion are blocked and bile acid levels rise inside the hepatocytes (e.g. 
cholestasis), the xenosensors are activated by these elevated bile acid levels 
and subsequently promote alternate mechanisms in order to lower intrahepatic 
bile acid levels before they become hepatotoxic. In summary, the four nuclear 
receptors FXR, PXR, CAR, and VDR are functionally related inasmuch as they 
coordinately reduce hepatic bile acid levels by increasing bile acid metabolism 
and export and in part by inhibiting de novo biosynthesis of bile acids from 
cholesterol [89]. 
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Among the drug-metabolizing CYPs, CYP3As are the major class of enzymes 
that hydroxylate bile acids [51, 90, 91]. Moreover, transcriptional induction of 
CYP3A genes by bile acids often exceeds that of CYP2B and CYP2C genes 
(refs. [92, 93] and Carmela Gnerre and U. A. M., unpublished observation). A 
number of findings suggest the presence of additional mechanisms for CYP3A 
regulation by bile acids. FXR-mediated induction of SHP by bile acids decreases 
the transcriptional activity of PXR [94]. Moreover, in mice with transgenically 
incorporated human CYP3A4 5’-flanking region linked to a reporter gene, 
increase in CYP3A4-driven reporter gene expression is not primarily dependent 
on the levels of circulating lithocholic acid, the primary bile acid-ligand of mouse 
PXR [95]. FXR activates CYP3A4 drug-responsive enhancer elements and might 
thus directly increase CYP3A levels [51, 83]. Alternatively, CYP3A is also 
induced by CAR which can bind to the same drug-responsive elements as PXR 
[11]. Finally, VDR is also activated by bile acids and can induce transcription of 
CYP3As in liver and intestine [87]. However, the role of the different bile acids in 
the CYP3A regulation and the receptors mediating this induction remain to be 
elucidated. 
 
Human CYP3A4, but not CYP1A2, CYP2C9 or CYP2B6, catalyzes both 6- and 
4-hydroxylation of cholesterol [96]. Interestingly, patients treated with the anti-
epileptic drugs phenobarbital, carbamazepine or phenytoin have up to 20 fold 
elevated plasma levels of 4-hydroxycholesterol whereas fecal levels of patients 
and control subjects are comparable [96]. The 52 hours half-life of this oxysterol 
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in plasma is extremely long compared to other oxysterols, e.g. 24-
hydroxycholesterol with a half-life of 12 hours or 27-hydroxycholesterol and 7-
hydroxycholesterol, which have half-lifes shorter than 0.75 hours and 0.5 hours in 
human circulation, respectively [97]. Moreover, 4-hydroxycholesterol is a poor 
substrate for 7-hydroxylations by CYP7A1 whereas the two oxysterol 7-
hydroxylases CYP7B1 and CYP39A1 have no catalytic activity toward 4-
hydroxycholesterol [97]. It seems that upon activation of PXR, elevated CYP3A 
levels catalyze 4-hydroxylation of cholesterol resulting in a steep increase in the 
plasma levels of 4-hydroxycholesterol [96, 97]. Subsequently, this oxysterol is a 
potent activator of LXR [34]. Another major hepatic cholesterol metabolite, the 
oxysterol 24(S),25-epoxycholesterol is an activator of both mouse PXR and 
LXR [98]. Interestingly, intrahepatic levels of the 24(S),25-epoxycholesterol 
enantiomer increase after mevalonate administration in rats suggesting that this 
oxysterol is a key mediator of the effect of mevalonate on downregulation of 
HMG-CoA reductase and on induction of CYP7A1 activity [99]. This overlap in 
ligands and the PXR-induced production of LXR activators thus further promotes 
cholesterol metabolism and excretion in a coordinate action between PXR and 
LXR.  
 
The predominant bile acid hydroxylations catalyzed by CYP3As are 6-
hydroxylation reactions which are stimulated in hepatocytes by rifampicin, a 
strong activator of human PXR [90, 100]. Both 6-hydroxylated 
chenodeoxycholic acid (hyocholic acid) as well as 6-hydroxylated lithocholic 
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acid (hyodeoxycholic acid) are selective activators of LXR [93, 101]. Treatment of 
hepatoma cells with hyocholic acid or hyodeoxycholic acid reduces the levels of 
drug-induced CYPs [93]. LXR binds to drug-responsive enhancer elements in the 
chicken CYP2H1 and the human CYP2B6 and CYP3A4 5’-flanking regions [93]. 
One possible mechanistic explanation for these observations is binding of LXR to 
these elements followed by competition with the binding of the xenosensors and 
a resulting decreased transcriptional activity of the drug-responsive enhancers 
[93, 102]. Thus, LXR forms a negative feedback loop on the drug-inducible CYPs 
catalyzing the hydroxylation reactions of bile acids which result in LXR agonists. 
This mechanism probably ensures protection from accumulation of hydroxylated 
bile acids in the liver. 
 
NR1I subfamily members regulate lipid levels in the liver 
 
In addition to cholesterol and bile acid homeostasis, LXR and FXR play 
diametrically opposed roles in the regulation of lipid biosynthesis. LXR is a strong 
activator of SREBP-1c and thus triggers an increase in triglyceride biosynthesis 
in the liver [103, 104]. Moreover, independent of SREBP-1c, LXR directly 
activates other lipogenic genes including fatty acid synthase (FAS) [105]. In 
contrast, FXR transcription is increased in the fasting liver by the peroxisome 
proliferator activated receptor  coactivator 1 (PGC-1) [106]. The interaction 
between FXR and PGC-1 results in an induction of genes that promote 
triglyceride clearance and fatty acid -oxidation concomitantly with a reduction of 
  - 16 - 
lipogenic gene transcription [106]. Among the FXR-target genes, SHP is the 
major inhibitor of SREBP-1c induction by LXRs [107]. Another strong activator of 
fatty acid metabolism, the peroxisome proliferator activated receptor  (PPAR, 
NR1C1), also antagonizes LXR function and vice versa [108]. In the fasted liver 
with high levels of fatty acid -oxidation, PPAR interferes with LXR-mediated 
induction of SREBP-1c [109]. On the other hand, activated LXR reduces PPAR 
binding to fatty acid-metabolizing gene promoters [110]. The role of the 
xenobiotic-sensing nuclear receptors in triglyceride homeostasis has not been 
extensively studied. However, a number of findings suggest a role for CAR and 
PXR in this process. First, CAR can bind to DNA-elements overlapping with 
those for PPAR in the promoter of enoyl-CoA hydratase/3-hydroxyacyl-CoA 
dehydrogenase, the second enzyme of peroxisomal fatty acid -oxidation [111]. 
PPAR signaling on the other hand influences CAR-mediated hepatocyte 
proliferation after drug-treatment [112]. Phenobarbital induces Cyp4a10 and 
Cyp4a14, two CYPs involved in peroxisomal fatty acid oxidation, but only in the 
CAR null background suggesting an inhibitory role of CAR on these genes [41]. 
Moreover, CAR localization in the nucleus is affected by its binding to PGC-1 
[113], a strong transcriptional coactivator that is regulated in the liver by fasting 
and feeding [114]. Finally, during caloric restriction, CAR is a regulator of thyroid 
hormone levels [115]. Thus, by increasing thyroid hormone metabolism, CAR 
contributes to the body’s resistance to weight loss [115]. Recent studies 
furthermore suggested that CAR in the brain is involved in the regulation of 
dexamethasone levels in the brain which in turn influence the levels of the 
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glucocorticoid-receptor target genes neuropeptide Y and the neuropeptide Y 
receptor subtype 1 in mice [116]. This has potential implications in the regulation 
of food intake in these animals. However, very high concentrations of 
dexamethasone were used in this study and the physiological relevance of this 
observation in vivo is thus not clear. 
 
Experimental and clinical observations 
 
A functional link between xenobiotics and lipid levels has been confirmed by a 
number of observations and findings in cell culture, animals and patients. As 
examples, blocking of de novo cholesterol biosynthesis using different inhibitors 
such as squalestatin, lovastatin or fluvastatin increases CYP2B1/2 in rat primary 
hepatocytes and in rat liver in vivo [117-119]. Phenobarbital-treatment of rats 
changed the expression of various genes in the cholesterol-biosynthesis pathway 
[120-122] whereas rats fed a high-cholesterol diet or spontaneous hyperlipidemic 
rats with elevated cholesterol levels have a reduced basal and phenobarbital-
induced CYP2B levels [123, 124]. Furthermore, PB-induction of CYP2Bs in 
obese fa/fa Zucker rats is almost completely lost [125]. In contrast, nutritional 
obesity has very small and enzyme-specific effects on PB-induction of various 
CYPs [126, 127]. Long-term treatment of rats with phenobarbital leads to 
considerable changes in the lipoprotein levels [128, 129]. Serum biochemistry 
and microarray analysis of rats that were repeatedly treated with phenobarbital 
show induced cholesterogenesis with a corresponding elevation in serum total 
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cholesterol, impaired glycolysis and stimulated lipolysis in the liver [122]. 
Treatment of rats and with imidazoles also resulted in elevated plasma HDL 
levels and expression of hepatic apolipoprotein A1 [130]. Interestingly, this 
elevation of cholesterol and apolipoprotein A1 levels was only observed in wild-
type but not in PXR knockout mice [130]. 
The widespread, long-term use of phenobarbital as an anti-epileptic drug allowed 
a number of studies regarding the effect of phenobarbital on lipid profiles in 
patients. Several groups reported significant changes in plasma and hepatic lipid 
profiles, especially after long-term treatment (e.g. see refs. [131-136]) whereas 
other studies failed to detect a significant correlation between phenobarbital 
treatment and changes in lipid levels (e.g. see ref. [137]). It is possible that 
induction of cholinesterase in epileptic patients treated with phenobarbital 
contributes to the changes in lipid levels [138]. Beneficial effects of phenobarbital 
on hyperbilirubinemia [139] and of phenobarbital and rifampicin on cholestasis 
[140] have been observed for decades. Recently, the xenosensors PXR and 
CAR have been identified to mediate at least some of these therapeutic effects 
[50, 51, 57, 141]. 
 
Species differences in hepatic detoxification 
 
Marked differences in the way different species deal with foreign compounds 
have been described [53, 142]. First, CYP orthologs differ in their basal 
expression in different species: e.g., CYP3As are very abundant in humans and 
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key enzymes in steroid and xenobiotic metabolism whereas CYP3A levels, in the 
absence of induction, are relatively low in rodents [143]. In addition, these genes 
are differentially induced by drugs and other xenobiotics. As example, human, 
but not rodent CYP3As are strongly induced by rifampicin. In contrast, 
pregnenolone 16-carbonitrile very potently increases mouse and rat CYP3As 
whereas it hardly changes human CYP3A4 levels [142]. Moreover, when drug-
responsive elements in the 5’-flanking regions of CYPs were isolated, no 
apparent feature conserved between species was found (e.g. see ref. [144]). For 
years, it was therefore not clear whether these species use similar molecular 
mechanisms for hepatic detoxification [145]. These species differences make 
extrapolation of pharmacokinetic and pharmacodynamic data from animal 
models to man virtually impossible. 
 
The discovery of the drug-sensing nuclear receptors PXR and CAR was a 
breakthrough in understanding the species-specific differences in hepatic drug 
detoxification. It turned out that many aspects of drug-induction of CYPs by 
nuclear receptors are highly conserved in evolution [28, 146-148]. As example, 
the mammalian xenosensors and the chicken xenobiotic receptor (CXR) [149] 
can be used interchangeably in many cell culture-based assays [146]. Also, 
despite their sequence differences, drug-responsive elements found in CYP 5’-
flanking regions from rodents, man and chicken can be activated by the 
xenobiotic-sensing nuclear receptors from all of these species [146]. Like its 
mammalian orthologs, CXR is activated by drugs, other xenobiotics and bile 
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acids [93, 149]. The high specificity of certain compounds to induce CYPs in a 
species-selective way can largely be explained by the divergent ligand-binding 
domains of the xenosensor orthologs [8, 25, 53]. Thus, rifampicin is a good 
ligand for human PXR, but not for the rodent ortholog whereas pregnenolone 
16-carbonitrile only activates mouse PXR. 
 
Other aspects in the biology of the NR1I and NR1H nuclear receptors show 
divergent evolution. Foremost, the two xenosensors, PXR and CAR have only 
been found in mammals whereas other vertebrate genomes including fish or 
chicken encode only one xenosensor [28, 149, 150]. Similarly, only one 
xenobiotic-sensing nuclear receptor has been found in the C. elegans genome 
[151]. Future studies may show why mammals have two xenosensors and how 
those affect drug-induction and lipid homeostasis. However, in addition to the 
species-specificity in the drug-detoxification machinery, there are considerable 
variations in the hepatic lipid homeostasis. Distinct serum lipoprotein levels have 
been found in different species (e.g., see ref. [152]). Another example, the 
different regulation of CYP7A1 by LXR in mice, rats and man has been 
discussed above. Extrapolation of data obtained in rodents regarding drug 
regulation of lipid homeostasis might therefore only be of limited use. 
 
Conclusions 
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Although it appears paradoxical because the potential for drug-drug interactions 
and adverse drug reactions may increase [153], therapeutic targeting of CAR and 
PXR might be beneficial under certain conditions. Inhibition of CAR either by 
genetic ablation or by using CAR inverse agonists decreases acetaminophen-
induced hepatotoxicity [154]. On the other hand, increasing CAR activity most 
likely ameliorates neonatal jaundice by increasing bilirubin conjugation and 
clearance [155]. Moreover, drug-mediated activation of both PXR and CAR is 
potentially beneficial in cholestasis [156]. Increasing our knowledge of the 
functions of CAR and PXR in hepatic detoxification as well as their roles in 
regulating lipid homeostasis in concert with other nuclear receptors such as FXR, 
LXR and PPAR could lead to novel approaches in the therapy of diseases 
related to these processes. In summary, work on CAR and PXR in recent years 
clearly shows that these nuclear receptors are more than mere xenosensors. 
Both receptors seem to be involved in the regulation of a variety of endogenous 
pathways and thus not only respond to xenobiotic challenges, but also to 
metabolic and nutritional stress [157]. 
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Figure Legends 
 
Figure 1. Phylogenetic tree of the nuclear receptors from the subfamilies 
NR1I and NR1H. The tree was generated comparing the full-length amino acid 
sequences of the respective receptors and shows the relationship between the 
drug-sensing nuclear receptors CAR (NR1I3), PXR (NR1I2), the vitamin D3-
receptor VDR (NR1I1), the bile acid-activated FXR (NR1H4) and the oxysterol-
sensing LXR/ (NR1H3/2) from different species. The scale bar represents 0.1 
amino acid substitution per site. 
 
Figure 2. Endogenous and xenobiotic lipophilic compounds activate a 
number of nuclear receptors which control their intra- and extra-hepatic 
levels. The members of the nuclear receptor subfamilies NR1I and NR1H are 
activated by various xenobiotics and endogenous lipids. In general, the receptors 
subsequently regulate the metabolism and excretion of these compounds. A high 
redundancy exists for several substance classes to bind to multiple receptors. 
See text for details. 
 
Figure 3. FXR, LXR, PPAR, CAR, PXR, and VDR control hepatic lipid 
homeostasis. Oxysterol-activated LXR increases metabolism of cholesterol to 
bile acids. Moreover, LXR also stimulates lipogenesis by inducing SREBP-1c and 
other lipogenic genes. Simultaneously, LXR inhibits PPAR-mediated fatty acid 
oxidation by interfering with PPAR-binding to its target sites. In contrast, 
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PPAR, FXR, CAR, PXR and VDR have counter-regulatory effects on LXR in the 
regulation of triglyceride as well as cholesterol and bile acid levels. Moreover, 
xenosensor and LXR functions are diametrically opposed in the regulation of 
drug- and bile acid-metabolizing CYPs. See text for details. 
 
Figure 1 (EPS)
Figure 2 (EPS)
Figure 3 (EPS)
